Low-dose combinations of LBH589 and TRAIL can overcome TRAIL-resistance in colon cancer cell lines

Anticancer Research

Volumn 31, Issue 10, 2011, Pages 3385-3394

  Lee, Sang Cheol ^a   Cheong, Hee Jeong ^a   Kim, Sook Ja ^a   Yoon, Jina ^b   Kim, Han Jo ^a   Kim, Kyoung Ha ^a   Kim, Se Hyoung ^b   Kim, Hyun Jung ^b   Bae, Sang Byung ^a   Kim, Chan Kyu ^b   Lee, Namsu ^a   Lee, Kyu Taeg ^a   Park, Sung Kyu ^b   Hong, Dae Sik ^b   Park, Hee Sook ^a   Won, Jong Ho ^a  

^a Soonchunhyang University   (South Korea)

^b Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Apoptosis; Colon cancer; Histone deacetylase inhibitor; LBH589; TRAIL

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; DEATH RECEPTOR 4; DEATH RECEPTOR 5; HISTONE H3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PANOBINOSTAT; PROTEIN BCL 2; PROTEIN BID; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL STRAIN HCT116; CELL STRAIN HT29; CELL SURVIVAL; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME ACTIVATION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; LOW DRUG DOSE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACETYLATION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASES; CELL PROLIFERATION; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HCT116 CELLS; HISTONES; HT29 CELLS; HUMANS; HYDROXAMIC ACIDS; LEUKOCYTES, MONONUCLEAR; RECEPTORS, DEATH DOMAIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UMBILICAL CORD;

EID: 80054775001     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005. (Pubitemid 40372904)
2. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger and Starling N: Colorectal cancer. Lancet 375: 1030-1047, 2010.
3. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J and Dixit VM: The receptor for the cytotoxic ligand TRAIL. Science (Washington DC) 276: 111-113, 1997. (Pubitemid 27161256)
4. Ashkenazi A and Dixit VM: Death receptor: signaling and modulation. Science (Washington DC) 281: 1305-1308, 1998.
5. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C and Smith CA: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995. (Pubitemid 26091143)
6. Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD and Ashkenazi A: Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr Biol 6: 750-752, 1996. (Pubitemid 126656342)
7. Griffith TS, Chin WA, Jackson GC, Lynch DH and Kubin MZ: Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 161: 2833-2840, 1998. (Pubitemid 28425704)
8. Lee NS, Cheong HJ, Kim SJ, Kim SE, Kim CK, Lee KT, Park SK, Baick SH, Hong DS, Park HS and Won JH: Ex vivo purging of leukemia cells using tumor necrosis factor-related apoptosis-inducing ligand in hematopoietic stem cell transplantation. Leukemia 17: 1375-1383, 2003.
9. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC and Lynch DH: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999. (Pubitemid 29068521)
10. El-Deiry WS: The TRAIL to an anticancer agents. Drug Resist Updat 2: 79-80, 1999.
11. Keane MM, Ettenberg SA, Nau MM, Russell EK and Lipkowitz S: Chemotherapy augments TRAI- induced apoptosis in breast cancer cells. Cancer Res 59: 734-741, 1999. (Pubitemid 29076075)
12. Gliniak B and Le T: Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo in enhanced by the chemotherapeutic agent CPT-11. Cancer Res 59: 6153-6158, 1999. (Pubitemid 30035636)
13. Kim K, Fisher MJ, Xu SQ and El-Deiry WS: Molecular determination of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 6: 335-346, 2000. (Pubitemid 30111448)
14. Byun JH, Hong YS, Cheong HJ, Kim SJ, Lee NS, Won JH, Hong DS and Park HS: Effect of arsenic trioxide in TRAIL (tumor necrosis factor-related apoptosis inducing ligand)-mediated apoptosis in multiple myeloma cell lines. Cancer Res Treat 35: 472-477, 2003.
15. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR and Strom SC: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6: 564-567, 2000. (Pubitemid 30305907)
16. Prince HM, Bishton MJ and Johnstone RW: Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 5: 601-612, 2009.
17. Bolden JE, Peart MJ and Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784, 2006. (Pubitemid 44348499)
18. Xu WS, Parmigiani RB and Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552, 2007. (Pubitemid 47255934)
19. Peart MJ, Smyth GK, van Laar RK Bowtell DD, Richon VM, Marks PA, Holloway AJ and Johnstone RW: Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 3697-3702, 2005. (Pubitemid 40354674)
20. Bhalla KN: Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23: 3971-3993, 2005.
21. Shao W, Growney JD, Feng Y, Wang P, Yan-Neale Y, O'Connor G, Kwon P, Yao Y, Fawell S and Atadja P: Potent anticancer activity of the pan-deacetylase inhibitor panobinostat (LBH589) as a single agent in in vitro and in vivo tumor models. AACR Annual Meeting, April 12-16, 2008, San Diego, CA, USA (poster presentation).
22. Atadja P: Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges. Cancer Letters 280: 233-241, 2009.
23. Bucur O, Ray S, Bucur MC and Almasan A: APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy. Front Biosci 11: 1549-1568, 2006. (Pubitemid 43253441)
24. Guo F, Sigua C, Tao J, Bali P, George P, Li Y, Wittmann S, Moscinski L, Atadja P and Bhalla K: Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 64: 2580-2589, 2004. (Pubitemid 38523916)
25. Kelley SK and Ashkenazi A: Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 4: 333-339, 2004. (Pubitemid 38987058)
26. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z and Schwall RH: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
27. Rowinsky EK: Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activiating agents. J Clin Oncol 23: 9394-9407, 2005.
28. Ren YG, Wagner KW, Knee DA, Aza-Blanc P, Nasoff M and Deveraux QL: Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle. Mol Biol Cell 15: 5064-5074, 2004. (Pubitemid 39392220)
29. Van Geelen CM, Pennarun B, Ek WB, Le PT, Spierings DC, De Vries EG and De Jong S: Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines. Int J Oncol 37: 1031-1041, 2010.
30. Fandy TE, Shankar S, Ross DD, Sausville E and Srivastava RK: Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 7: 646-657, 2005. (Pubitemid 41099418)
31. Symanowski J, Vogelzang N, Zawel L, Atadja P, Pass H and Sharma S: A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL. J Thorac Oncol 4: 149-160, 2009.
32. Kauh J, Fan S, Xia M, Yue P, Yang L, Khuri FR and Sun SY: c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS One 5: e10376, 2010.
33. Elrod HA and Sun SY: Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther 7: 163-173, 2007.
34. Wang S: The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 237: 6207-6215, 2008.
35. Huang S, Okumura K and Sinicrope FA: BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human prostate cancer cells. Clin Cancer Res 15: 150-159, 2009.
36. Deveraux QL, Takahashi R, Salvesen GS and Reed JC: X-Linked IAP is a direct inhibitor of cell-death proteases. Nature 388: 300-304, 1997. (Pubitemid 27317977)
37. Vogler M, Durr K, Jovanovic M, Debatin KM and Fulda S: Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 26: 248-257, 2007. (Pubitemid 46095735)
38. Jani TS, DeVecchio J, Mazumbar T, Agyeman A and Houghton JA: Inhibition of NF-kB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem 285: 19162-19172, 2010.
39. Ammann JU, Haag C, Kasperczyk H, Debatin KM and Fulda S: Sensitization of neuroblastoma cells for TRAIL-induced apoptosis by NF-kappaB inhibition. Int J Cancer 124: 1301-1311, 2009.